Overview

  • Product nameRanBP2 peptide

Description

  • NatureSynthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab4939 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking

  • FormLiquid
  • Additional notes


    This peptide may be used for neutralization and control experiments with the polyclonal antibody that reacts with this product and human RanBP 2, catalog ab2938. Using a solution of peptide of equal volume and concentration to the corresponding antibody will yield a large molar excess of peptide (~ 70-fold) for competitive inhibition of antibody-protein binding reactions.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.

General Info

  • Alternative names
    • 358 kDa nucleoporin
    • ANE1
    • E3 SUMO-protein ligase RanBP2
    • IIAE3
    • Nuclear pore complex protein Nup358
    • Nucleoporin 358
    • Nucleoporin Nup358
    • NUP358
    • p270
    • RAN binding protein 2
    • Ran-binding protein 2
    • RANBP2
    • RBP2_HUMAN
    • Transformation related protein 2
    • TRP 1
    • TRP 2
    • TRP1
    • TRP2
    see all
  • FunctionE3 SUMO-protein ligase which facilitates SUMO1 and SUMO2 conjugation by UBE2I. Involved in transport factor (Ran-GTP, karyopherin)-mediated protein import via the F-G repeat-containing domain which acts as a docking site for substrates. Could also have isomerase or chaperone activity and may bind RNA or DNA. Component of the nuclear export pathway. Specific docking site for the nuclear export factor exportin-1.
  • PathwayProtein modification; protein sumoylation.
  • Involvement in diseaseDefects in RANBP2 are the cause of susceptibility to encephalopathy acute necrotizing type 1 (ANE1) [MIM:608033]. A rapidly progressive encephalopathy manifesting in susceptibile individuals with seizures and coma. It can occur within days in otherwise healthy children after common viral infections such as influenza and parainfluenza, without evidence of viral infection of the brain or inflammatory cell infiltration. Brain T2-weighted magnetic resonance imaging reveals characteristic symmetric lesions present in the thalami, pons and brainstem.
  • Sequence similaritiesContains 1 PPIase cyclophilin-type domain.
    Contains 4 RanBD1 domains.
    Contains 8 RanBP2-type zinc fingers.
    Contains 1 TPR repeat.
  • DomainContains F-X-F-G repeats.
  • Post-translational
    modifications
    Polyubiquitinated by PARK2, which leads to proteasomal degradation.
  • Cellular localizationNucleus > nuclear pore complex. Cytoplasmic filaments.
  • Information by UniProt

References for RanBP2 peptide (ab4939)

ab4939 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab4939.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"